News

 

At AseBio, we follow the latest news in the biotechnology sector and pass the highlights on to you. You can use the search engine to find news articles we’ve written, contributed by our members or from other stakeholders in the sector. And they are also organised into categories to help you find the topics you’re interested in easily.

Search engine
bayer
Bayer and Mammoth Biosciences to collaborate on novel gene editing technology
Healthcare · Gene editing
Agreement strengthens Bayer’s new cell and gene therapy platform further / Supports Mammoth’s…
imagen AKRN
Amendment for the transition of in vitro diagnostic medical devices (IVDs) to the EU 2017/746 (IVDR)
This amendment aims to extend the scope and timelines for the transition to the new regulation and…
illumina
Multiomics is revolutionizing research, here’s why
Learn why research leaders decided to use Multiomics in their work.  
illumina
Introducing Illumina Connected Analytics
Healthcare · Agrifood · Gene editing · International
Analyze, manage, aggregate, and explore data at scale with Illumina Connected Analytics, a…
enero 2022 bcn
BCN HEALTH publishes a study evaluating the influence of disease severity on healthcare costs among hospitalized NAFLD/NASH patients in Spain
BCN HEALTH realizó un estudio retrospectivo basado en los registros de pacientes hospitalizados por…
foto oryzon
ORYZON announces approval for Serbian arm of PORTICO, vafidemstat’s Phase IIb trial in Borderline Personality Disorder
Healthcare
Serbian arm final deployment in PORTICO. Study already active in Spain, Bulgaria, Germany and USA…
oryzon
ORYZON to hold multiple corporate activities in January
Healthcare · Advanced therapies
40º Annual J.P. Morgan Healthcare Conference Biotech Showcase 2022 11º Annual LifeSci Partners…
ITEMAS
GENESIS Biomed sponsors the ITEMAS 2021 Annual Conference
The Instituto Aragonés de Ciencias de la Salud (IACS) and the Instituto de Investigación Sanitaria…
oryzon pic
ORYZON at ASH-2021: iadademstat 36-month ALICE data demonstrate robust efficacy in combination with azacitidine in AML
Healthcare
Robust efficacy - ORR 78%, of which 62% are CR/CRi 77% of CR/CRi lasting more than 6 months…